Broken redirects

Jump to navigation Jump to search

The following redirects link to non-existent pages:

Showing below up to 27 results in range #2,321 to #2,347.

View ( | next 50) (20 | 50 | 100 | 250 | 500)

  1. Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience → Special:Badtitle/NS100:Even Crossing State Lines Improves Time to Treatment for STEMI : Mayo Clinic experience
  2. Excel biodegradable stents are safe and effective: Results from the CREATE trial → Special:Badtitle/NS100:Excel biodegradable stents are safe and effective: Results from the CREATE trial
  3. ExoSeal® Vascular Closure Device is safe and effective → Special:Badtitle/NS100:ExoSeal® Vascular Closure Device is safe and effective
  4. Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection → Special:Badtitle/NS100:Expression of programmed death ligand-1 in donor hearts regulates chronic allograft rejection
  5. Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI → Special:Badtitle/NS100:Extended Use of Clopidogrel is Associated with Reduction in Death or Death and Non-fatal Myocardial Infarction among Diabetics following PCI
  6. Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis → Special:Badtitle/NS100:Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis
  7. F.I.R.E. Study Misses Primary Endpoint → Special:Badtitle/NS100:F.I.R.E. Study Misses Primary Endpoint
  8. FDA Advisors Under Review for the Potential of Financial Conflict. August 8, 2007 → Special:Badtitle/NS100:FDA Advisors Under Review for the Potential of Financial Conflict
  9. FDA Panel Recommends Approval of New DES → Special:Badtitle/NS100:FDA Panel Recommends Approval of New DES
  10. FDA Requires Stronger Heart Failure Warning for Avandia and Actos → Special:Badtitle/NS100:FDA Requires Stronger Heart Failure Warning for Avandia and Actos
  11. FFR-guided PCI Reduces Incidence of Clinical Events in Patients with Multi-Vessel Disease: Results of the FAME Study → Special:Badtitle/NS100:FFR-guided PCI Reduces Incidence of Clinical Events in Patients with Multi-Vessel Disease: Results of the FAME Study
  12. Facilitated PCI: No Benefit in FINESSE → Special:Badtitle/NS100:Facilitated PCI: No Benefit in FINESSE
  13. Feedback regulation of catecholamines levels through an enzyme called renalase → Special:Badtitle/NS100:Feedback regulation of catecholamines levels through an enzyme called renalase
  14. Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry → Special:Badtitle/NS100:Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry
  15. Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial → Special:Badtitle/NS100:Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial
  16. Function of an obesity-associated gene defined → Special:Badtitle/NS100:Function of an obesity-associated gene defined
  17. IMAGINE reported: early ACE inhibitor therapy in low risk CABG patients associated with worse early outcomes → Special:Badtitle/NS100:IMAGINE reported: early ACE inhibitor therapy in low risk CABG patients associated with worse early outcomes
  18. New data on possible pro-thrombotic effects of pioglitazone → Special:Badtitle/NS100:New data on possible pro-thrombotic effects of pioglitazone
  19. Special:Badtitle/NS100:No Connection Between Vaccines & Autism, Original Data Faked in Lancet → Special:Badtitle/NS100:No Connection Between Vaccines & Autism, Original Data Faked in ''Lancet''
  20. No cardiovascular risk associated with coffee consumption after MI → Special:Badtitle/NS100:No cardiovascular risk associated with coffee consumption after MI
  21. Optimal does of aspirin following ST-elevation myocardial infarction → Special:Badtitle/NS100:Optimal does of aspirin following ST-elevation myocardial infarction
  22. PCI not Cost Effective in the Occluded Artery Trial (OAT) → Special:Badtitle/NS100:PCI not Cost Effective in the Occluded Artery Trial (OAT)
  23. RACE study: Statewide System for Coronary Reperfusion for STEMI Patients Can Improve Quality of Care → Special:Badtitle/NS100:RACE study: Statewide System for Coronary Reperfusion for STEMI Patients Can Improve Quality of Care
  24. STEMI patients: the untreated, reperfusion eligible. August 8, 2007 → Special:Badtitle/NS100:STEMI patients: the untreated, reperfusion eligible.
  25. Today in Medicine: Study on the Effect of Obesity on Mortality Rates Following MI → Special:Badtitle/NS100:Study on the Effect of Obesity on Mortality Rates Following MI
  26. The ARMYDA 4 Trial → Special:Badtitle/NS100:The ARMYDA 4 Trial
  27. Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI) ACC/AHA Guidelines Updated: August 7, 2007 → Special:Badtitle/NS100:Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI) ACC/AHA Guidelines Updated

View ( | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://www.wikidoc.org/index.php/Special:BrokenRedirects"